samedan logo
 
 
spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

CPhI & P-MEC India 2018

CPhI & P-MEC India

12-14 December 2018
India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.

CPhI & P-MEC India comes with the backing of the Delhi-based Pharmaceuticals Export Promotion Council of India (Pharmexcil) – the organisation behind key Government international strategies such as ‘Made in India’. Mr. Yogesh Mudras, Managing Director, UBM India commented “the shift to the Delhi-NCR region, in close geographical proximity to the policy makers, consulates and government bodies will enhance our community building efforts, as well as the creation of a robust pharma eco-system.”

UBM cited rising international interest in the event as a key factor in the move, with numbers of both international and domestic exhibitors requiring a far bigger venue – and on single site.

Mr Mudras added “I am delighted that CPhI & P-MEC India will be held this year at India Expo Mart, Greater Noida – it’s the flagship platform for the Indian pharma industry and one of the world’s leading Pharmaceutical networking events. It’s also a major international hub, with India’s largest airport and this venue change is looking ahead to future audience needs.”

The venue change is also seen as a boost to domestically focused markets by bringing a wider remit of attendees and greater access to national regulatory pathways. The country registers the second largest Abbreviated New Drug Applications (ANDAs) globally and is the world’s leader in Drug Master Files (DMFs) applications so access to regulatory expertise has never been greater.

The 2018 edition will also feature India Pharma Week (returning for a third year), with unique events and activities spanning the Indian Capital. These include dynamic engagements such as the Pharma Leader’s Golf, Pharma Connect Congress, Plant Visits, Women in Pharma – Power Breakfast, India Pharma Awards, Networking Evening, and a closed-door CEO Roundtable amongst others.  

The ultimate goal of all these intertwined events is to help nurture a complete pharma ecosystem in India and better enable networking with the country’s corridors of power. In fact, the recent CPhI Pharma Index showed India represents global pharma’s second fastest growing market and praised the Delhi based regulator, the CDSCO (Central Drugs Standard Control Organization) for its efforts in introducing a certification programme and initiatives for increased compliance. Impressively, 52% of international respondents believed the CDSCO is moving toward comparability with the regulatory standards of the EMA and FDA.

For more information and to register for the event: https://www.cphi.com/india/

phone +31 20 708 1728
email salesoperations@ubm.com
web https://www.cphi.com/india
email Delhi, India
 
Print this page
Send to a friend
   
spacer
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

Banner of DIA_Europe_Events_95 on Samedan Banner of Drug Delivery Partnership 2018_events_97 on Samedan

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>


News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement